Preclinical study shines a light on BET inhibitors' potential to prevent obesity-related cancer growth
A small molecule inhibitor of the bromodomain and extra-terminal protein family (BET) may slow down and even prevent the growth of breast and lung cancers, researchers report.
In two studies published in Cancer Prevention Research today, scientists showed that the drug compound, I-BET-762, had effects on both tumor and immune cells. As a result, it reduced the amount of existing cancer cells in mice by 80% and prevented 50% of precancerous human cells from becoming cancerous.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
